Literature DB >> 16426101

New developments in the treatment of ADHD.

Joseph Biederman1, Amy F T Arnsten, Stephen V Faraone, Alysa E Doyle, Thomas J Spencer, Timothy E Wilens, Margaret D Weiss, Steven A Safren, Larry Culpepper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16426101     DOI： 10.4088/jcp.v67n0121

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  11 in total

Review 1.  The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.

Authors:  Catharine A Winstanley
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Authors:  Michael Schlander
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

Review 3.  Poor response inhibition: at the nexus between substance abuse and attention deficit/hyperactivity disorder.

Authors:  Stephanie M Groman; Alex S James; J David Jentsch
Journal:  Neurosci Biobehav Rev       Date:  2008-08-22       Impact factor: 8.989

4.  Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.

Authors:  Jaswinder K Ghuman; Michael G Aman; Harinder S Ghuman; Thomas Reichenbacher; Alan Gelenberg; Ron Wright; Sydney Rice; Carolyn Fort
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-04       Impact factor: 2.576

Review 5.  Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.

Authors:  Michael J Manos
Journal:  Medscape J Med       Date:  2008-01-08

Review 6.  Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.

Authors:  Mostafa El Mansari; Bruno P Guiard; Olga Chernoloz; Ramez Ghanbari; Noam Katz; Pierre Blier
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

7.  Management of attention-deficit hyperactivity disorder.

Authors:  Rohit Verma; Yatan Pal Singh Balhara; Shachi Mathur
Journal:  J Pediatr Neurosci       Date:  2011-01

Review 8.  Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

Authors:  Alain Joseph; Rajeev Ayyagari; Meng Xie; Sean Cai; Jipan Xie; Michael Huss; Vanja Sikirica
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-03-03       Impact factor: 4.785

9.  DRD4 Gene Polymorphisms as a Risk Factor for Children with Attention Deficit Hyperactivity Disorder in Iranian Population.

Authors:  Seyed Mahmoud Tabatabaei; Shahrokh Amiri; Sara Faghfouri; Seyed Gholamreza Noorazar; Shahin AbdollahiFakhim; Ali Fakhari
Journal:  Int Sch Res Notices       Date:  2017-05-24

10.  Once-daily treatment of ADHD with guanfacine: patient implications.

Authors:  Brandon C Strange
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.